GRI Bio, Inc. (GRI)
(Delayed Data from NSDQ)
$0.51 USD
+0.02 (4.59%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $0.52 +0.01 (1.46%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for GRI Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 11 | 7 | 9 | 5 | 3 |
Income After Depreciation & Amortization | -11 | -7 | -9 | -5 | -3 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 2 | 0 | 0 | 0 | 0 |
Pretax Income | -13 | -7 | -9 | -5 | -3 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -7 | -9 | -5 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -13 | -7 | -9 | -5 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -7 | -9 | -5 | -3 |
Depreciation & Amortization (Cash Flow) | 2 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -11 | -7 | -9 | -5 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.04 | 0.00 | 0.00 | 0.00 | NA |
Diluted EPS Before Non-Recurring Items | -367.36 | -1,885.59 | -3,880.48 | -2,924.02 | NA |
Diluted Net EPS (GAAP) | -367.36 | -1,885.59 | -3,880.48 | -2,924.02 | NA |
Fiscal Year end for GRI Bio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 2.26 | 1.89 | 0.67 | 2.44 | 5.93 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.26 | -1.89 | -0.67 | -2.44 | -5.93 |
Non-Operating Income | 0.00 | 0.00 | 0.08 | 0.30 | 0.12 |
Interest Expense | -0.01 | -0.01 | 1.17 | -0.01 | 0.93 |
Pretax Income | -2.25 | -1.89 | -1.76 | -2.14 | -6.75 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.25 | -1.89 | -1.76 | -2.14 | -6.75 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.25 | -1.89 | -1.76 | -2.14 | -6.75 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 0.46 | 0.32 | NA | 0.05 | 0.03 |
Diluted EPS Before Non-Recurring Items | -4.92 | -5.98 | NA | -47.32 | -253.89 |
Diluted Net EPS (GAAP) | -4.92 | -5.98 | 418.88 | -47.32 | -253.89 |